Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,790 | -7,793 | -6,615 | -4,301 | -3,362 |
| Depreciation Amortization | 2 | 7 | 5 | 2 | 2 |
| Income taxes - deferred | N/A | -1,700 | N/A | N/A | N/A |
| Accounts receivable | N/A | 106 | 106 | 106 | 106 |
| Accounts payable and accrued liabilities | -897 | 543 | -320 | -356 | 711 |
| Other Working Capital | -1,071 | 719 | -280 | -213 | 770 |
| Other Operating Activity | 14,535 | -751 | -70 | -182 | -28 |
| Operating Cash Flow | $-3,221 | $-8,869 | $-7,174 | $-4,944 | $-1,801 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 4,040 | 4,040 | N/A | N/A |
| Other Financing Activity | 0 | -327 | -327 | -327 | -327 |
| Financing Cash Flow | $N/A | $3,713 | $3,713 | $-327 | $-327 |
| Beginning Cash Position | 16,977 | 22,133 | 22,133 | 22,133 | 22,133 |
| End Cash Position | 13,756 | 16,977 | 18,672 | 16,862 | 20,005 |
| Net Cash Flow | $-3,221 | $-5,156 | $-3,461 | $-5,271 | $-2,128 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,221 | -8,869 | -7,174 | -4,944 | -1,801 |
| Free Cash Flow | -3,221 | -8,869 | -7,174 | -4,944 | -1,801 |